Oncology Central

Commercial-automated platform for isolating circulating tumor cells developed

0
Researchers from Society for Laboratory Automation and Screening (IL, USA) have developed a novel commercial-automated platform for isolating circulating tumor cells (CTCs), termed the VTX-1 Liquid Biopsy System. The findings were published recently in SLAS Technology.

The platform, which is designed to automate the isolation of clinically relevant CTC populations, represents the transition from a cutting-edge microfluidic innovation in the lab to a commercial-automated system for isolating CTCs directly from whole blood.

To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.